May 25, 2022
The day after
Although nothing official has been announced many seem to believe that the Dexcom acquisition of Insulet is a fete accompli. Which is interesting as today so far anyway Dexcom shares are recovering while Insulet are only slightly off. It should also be noted that Tandem shares are up today as well and yes Tandem is part of this deal. For our part we put the chance at this deal being finalized at 70/30 in favor of a deal.
Even before it becomes official the wheels are in motion that likely will change the diabetes landscape. The two biggest . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.